Spectral AI Announces Repricing of its Public Warrants
Spectral AI (NASDAQ: MDAI) announced the repricing of its 8,433,333 publicly-traded common share purchase warrants from $11.50 to $2.75 per share. The warrants, trading under symbol MDAIW, will be repriced following a twenty-day notice period to warrant holders. If all warrants are exercised for cash, the company could receive up to $23 million in net proceeds. The repricing applies uniformly to all outstanding warrants and was executed under the Company's discretion as permitted by the Warrant Agreement.
Spectral AI (NASDAQ: MDAI) ha annunciato la riduzione del prezzo delle sue 8.433.333 opzioni di acquisto di azioni comuni quotate in borsa da $11,50 a $2,75 per azione. Le opzioni, quotate con il simbolo MDAIW, saranno riconsiderate dopo un periodo di preavviso di venti giorni per i titolari delle opzioni. Se tutte le opzioni vengono esercitate per contanti, l'azienda potrebbe ricevere fino a $23 milioni in proventi netti. La riduzione del prezzo si applica uniformemente a tutte le opzioni in circolazione ed è stata eseguita sotto la discrezione dell'azienda come consentito dall'Accordo sulle Opzioni.
Spectral AI (NASDAQ: MDAI) anunció la revalorización de sus 8,433,333 garantías de compra de acciones comunes que cotizan en bolsa, de $11.50 a $2.75 por acción. Las garantías, que se negocian bajo el símbolo MDAIW, se revalorizarán después de un periodo de aviso de veinte días a los tenedores de las garantías. Si se ejercen todas las garantías por efectivo, la compañía podría recibir hasta $23 millones en ingresos netos. La revalorización se aplica uniformemente a todas las garantías en circulación y se llevó a cabo bajo la discreción de la compañía tal como lo permite el Acuerdo de Garantías.
스펙트럴 AI (NASDAQ: MDAI)는 8,433,333개의 공개 거래되는 보통주 매입 보증서의 가격을 주당 $11.50에서 $2.75로 조정했다고 발표했습니다. MDAIW 상징으로 거래되는 이 보증서는 보증서 소유자에게 20일의 고지 기간 이후에 가격이 조정됩니다. 모든 보증서가 현금으로 행사되면 회사는 최대 $2300만의 순수익을 받을 수 있습니다. 이 가격 조정은 모든 보증서에 균일하게 적용되며, 보증서 계약에서 허용된 대로 회사의 재량에 따라 실행되었습니다.
Spectral AI (NASDAQ: MDAI) a annoncé la revalorisation de ses 8 433 333 bons de souscription d'actions ordinaires cotés en bourse, de $11,50 à $2,75 par action. Les bons, négociés sous le symbole MDAIW, seront revalorisés après un préavis de vingt jours aux détenteurs de bons. Si tous les bons sont exercés en espèces, la société pourrait recevoir jusqu'à $23 millions de produits nets. La revalorisation s'applique uniformément à tous les bons en circulation et a été exécutée selon la discrétion de la société comme le permet l'Accord sur les Bons.
Spectral AI (NASDAQ: MDAI) hat die Neubewertung seiner 8.433.333 öffentlich gehandelten Kaufwarrants für Stammaktien von $11,50 auf $2,75 pro Aktie bekannt gegeben. Die Warrants, die unter dem Symbol MDAIW gehandelt werden, werden nach einer zwanzig-tägigen Ankündigungsfrist an die Inhaber der Warrants neu bewertet. Wenn alle Warrants gegen Bargeld ausgeübt werden, könnte das Unternehmen bis zu $23 Millionen an Nettomitteln erhalten. Die Neubewertung gilt einheitlich für alle ausgegebenen Warrants und wurde gemäß dem Ermessen des Unternehmens unter dem Warrants-Vertrag durchgeführt.
- Potential to raise up to $23 million in net proceeds if all warrants are exercised
- Significant reduction in warrant exercise price from $11.50 to $2.76, indicating potential share value deterioration
- Dilutive impact on existing shareholders if warrants are exercised
Insights
DALLAS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the repricing of its 8,433,333 publicly-traded common share purchase warrants with an exercise price of
Pursuant to the terms of the Warrant Agreement, each warrant entitles the registered holder to purchase shares of common stock at the specified price, subject to adjustments outlined in the Warrant Agreement. The repricing was executed in accordance with the Company's discretion, as permitted under the Warrant Agreement, and applies uniformly to all outstanding warrants. The Company shall provide at least twenty (20) days prior written notice of such reduction to the registered holders of the Warrants.
If all of the warrants are exercised for cash, Spectral AI may receive up to an aggregate of approximately
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize wound care management by "Seeing the Unknown®" with its DeepView® System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight toward value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intention to separate its Spectral IP subsidiary from the Company, and each Company’s strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Spectral AI undertakes no obligation to update any forward-looking statements except as otherwise required by law.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
What is the new exercise price for Spectral AI (MDAI) warrants?
How much could Spectral AI (MDAI) raise if all warrants are exercised?
How many warrants did Spectral AI (MDAI) reprice in November 2024?
What is the trading symbol for Spectral AI's warrants on NASDAQ?
